IN-VIVO EXPERIMENTATION OF TUPICHINOL E, OSIMERTINIB, AND THEIR COMBINATION USING A XENOGRAFT MODEL

This comprehensive study investigates the in vivo effects of Tupichinol E, osimertinib, and their combination in a xenograft model of triple-negative breast cancer (TNBC), an aggressive and therapeutically challenging breast cancer subtype. By employing a multi-faceted approach, the study evaluates tumor growth inhibition, apoptosis, and proliferation through histopathological and immunohistochemical techniques, including hematoxylin and eosin (H&E) staining, TUNEL staining, and Ki67 immunohistochemistry. The results reveal significant therapeutic potential. Tumor growth was markedly suppressed in all treated groups, with monotherapy using Tupichinol E or Osimertinib reduces tumor volume by approximately 35% and 40%, respectively. Notably, combination therapy achieved a synergistic effect, maintaining tumor volumes at baseline levels and preventing progression over the two-week treatment period (p<0.001). Histological analyses demonstrated extensive necrosis and disruption of tumor architecture in the combination group, correlating with a 150% increase in apoptotic activity as indicated by TUNEL staining (p<0.001). Furthermore, Ki67 immunohistochemistry showed a substantial 70% reduction in proliferative activity in the combination group compared to controls (p< 0.001). These findings underscore the enhanced efficacy of combining Tupichinol E and Osimertinib, offering a novel and promising therapeutic strategy for TNBC. The synergistic effects observed in tumor suppression, apoptosis induction, and proliferation inhibition highlight the potential for this combination to address unmet clinical needs in TNBC treatment. This study provides a foundation for future research to explore molecular mechanisms and clinical applicability of this combination therapy.